Pulmonary Disease Clinical Trial
Official title:
Factors That Impact the Relationship Between Pulmonary Status and Actual Electronic Cigarette Use (Secondary Data Analysis)
Verified date | October 2019 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Secondary data analysis will be performed as our approach to complete the study. A nationally representative dataset (BRFSS, 2017) will be used to answer the above hypotheses.
Status | Completed |
Enrollment | 400000 |
Est. completion date | December 30, 2017 |
Est. primary completion date | December 30, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
This is secondary data analysis, so there is no control over the data (inclusion criteria,
and exclusion criteria). Inclusion Criteria: Group 1: Pulmonary - Are 18 years of age or older. - Reported any of the pulmonary disease (Asthma, COPD). Group 2: Control Group - Are 18 years of age or older. - Free from any pulmonary disease (asthma, COPD). Exclusion Criteria Group 1: Pulmonary - Are younger than 18 years of age. - Did not report any of the pulmonary disease (Asthma, COPD). Group 2: Control Group - Are younger than 18 years of age. - Reported any pulmonary disease (asthma, COPD The Behavioral Risk Factor Surveillance System (BRFSS) is health-related telephone surveys that collect state data about United States residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services. This database contains data to help determine e-cigarette use in individuals with pulmonary disease in the US which little is known. Note: The Behavioral Risk Factor Surveillance System (BRFSS) is a public dataset, and the data is publicly available online at (https://www.cdc.gov/brfss/annual_data/annual_2017.html) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham |
Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2017].
Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Questionnaire. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2017]
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Poor mental health mediate the relationship between pulmonary status (pulmonary vs. non-pulmonary) and e-cigarette use. | This question assesses mental health, including stress, depression, and emotional problems, by asking participants the number of days out of the last 30 days that their mental health was not good (continuous variables). | 1 year | |
Primary | Smoking mediate the relationship between pulmonary status (pulmonary vs. non-pulmonary) and e-cigarette use. | Smoking: This scale assesses the frequency of smoking cigarettes: 1 = every day, 2 = some days, 3 = not at all. | 1 year | |
Primary | E-cigarette use (Dependent Variable) | This survey item asks participants if they ever used an e-cigarette or other electronic "vaping" product, even just one time, in their entire life (Yes/No). | 1 year | |
Primary | Alcohol use moderate the relationship between pulmonary status (pulmonary vs. healthy) and e-cigarette use | This question assesses the number of days in the last 30 days that participants have drunk alcohol (continuous variables). | 1 year | |
Primary | (healthy days (health-related quality of life) mediate the relationship between pulmonary status (pulmonary vs. non-pulmonary) and e-cigarette use. | In reference to healthy days, these questions assess health-related quality of life, which is going to be assessed by asking questions concerning the number of days out of the last 30 days that the participants were physically or mentally ill (continuous variables). | 1 year | |
Secondary | Marijuana use moderate the relationship between pulmonary status (pulmonary vs. healthy) and e-cigarette use. | This question assesses the number of days in the last 30 days that participants have used marijuana or hashish (continuous variables). | 1 year | |
Secondary | Severity of COPD symptoms (COPD group) moderate the relationship between pulmonary status (COPD, asthma) and e-cigarette use | Three questions are posed to assess the severity of COPD symptoms. The responses of these questions are combined to form a composite score. The first question will assess coughing, the second question will assess phlegm production, and the third question will assess shortness of breath. Answers for each of the three questions will be in a yes/no format and will be represented on a scale of 1?3, where 1 is less severe and 3 is more severe. | 1 year | |
Secondary | asthma symptoms (asthmatic group) moderate the relationship between pulmonary status (COPD, asthma) and e-cigarette use. | Several questions determine the severity of asthma symptoms. The first question will assess the asthma symptoms by asking the participants the number of days they were unable to work or carry out their usual activities because of their asthma symptoms (continuous variables). The second question will assess coughing, wheezing, shortness of breath, chest tightness and phlegm production by asking participants the number of days out of the last 30 that they have any of the previous symptoms (continuous variables). The final question will symptoms of asthma make it difficult for the participants to stay asleep (continuous variables). | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT02504697 -
DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
|
||
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Terminated |
NCT00524095 -
Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis
|
Phase 2 | |
Completed |
NCT00210249 -
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
|
||
Completed |
NCT00023114 -
p450 Mediated Lung Toxicity
|
N/A | |
Recruiting |
NCT06056882 -
Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
|
||
Completed |
NCT03994848 -
Incentive Spirometry Prehabilitation Study
|
N/A | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Withdrawn |
NCT05100160 -
Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)
|
Phase 3 | |
Completed |
NCT03229473 -
Fall Risk Assessment in COPD
|
||
Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT04996693 -
On Dose Efficiency of Modern CT-scanners in Chest Scans
|
N/A | |
Recruiting |
NCT04996173 -
Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)
|
N/A | |
Completed |
NCT04601545 -
The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method
|
N/A | |
Recruiting |
NCT03937583 -
Screening for Cancer in Patients With Unprovoked VTE
|
Phase 4 | |
Recruiting |
NCT02862418 -
Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)
|